NCT05860374View on ClinicalTrials.gov

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 2, 2023

Primary Completion Date

March 2, 2025

Study Completion Date

March 2, 2026

Conditions
SarcomaCarcinomaBreast CancerPancreatic CancerColorectal CancerGastric CancerLiver CancerLung CancerGynecologic Cancer
Interventions
DRUG

Recombinant oncolytic herpes simplex virus type 1 (R130)

R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11

Trial Locations (1)

221000

RECRUITING

Xuzhou Second People's Hospital, Shanghai

All Listed Sponsors
collaborator

The Affiliated Hospital of Xuzhou Medical University

OTHER

lead

Shanghai Yunying Medical Technology

INDUSTRY